Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.

Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Schüle B, Dolmetsch RE, Langston W, Palmer TD, Pera RR.

Cell Stem Cell. 2011 Mar 4;8(3):267-80. doi: 10.1016/j.stem.2011.01.013.

2.

Modeling Parkinson's disease using induced pluripotent stem cells.

Byers B, Lee HL, Reijo Pera R.

Curr Neurol Neurosci Rep. 2012 Jun;12(3):237-42. doi: 10.1007/s11910-012-0270-y. Review.

3.

Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.

Liu G, Sgobio C, Gu X, Sun L, Lin X, Yu J, Parisiadou L, Xie C, Sastry N, Ding J, Lohr KM, Miller GW, Mateo Y, Lovinger DM, Cai H.

Hum Mol Genet. 2015 Sep 15;24(18):5299-312. doi: 10.1093/hmg/ddv249.

4.

Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.

Reinhardt P, Schmid B, Burbulla LF, Schöndorf DC, Wagner L, Glatza M, Höing S, Hargus G, Heck SA, Dhingra A, Wu G, Müller S, Brockmann K, Kluba T, Maisel M, Krüger R, Berg D, Tsytsyura Y, Thiel CS, Psathaki OE, Klingauf J, Kuhlmann T, Klewin M, Müller H, Gasser T, Schöler HR, Sterneckert J.

Cell Stem Cell. 2013 Mar 7;12(3):354-67. doi: 10.1016/j.stem.2013.01.008.

5.

Parkinson's disease in a dish - Using stem cells as a molecular tool.

Badger JL, Cordero-Llana O, Hartfield EM, Wade-Martins R.

Neuropharmacology. 2014 Jan;76 Pt A:88-96. doi: 10.1016/j.neuropharm.2013.08.035. Review.

PMID:
24035919
6.

LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.

Heo HY, Park JM, Kim CH, Han BS, Kim KS, Seol W.

Exp Cell Res. 2010 Feb 15;316(4):649-56. doi: 10.1016/j.yexcr.2009.09.014.

PMID:
19769964
7.

Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.

Schwab AJ, Ebert AD.

Stem Cell Reports. 2015 Dec 8;5(6):1039-52. doi: 10.1016/j.stemcr.2015.11.004.

8.

Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.

Liu GH, Qu J, Suzuki K, Nivet E, Li M, Montserrat N, Yi F, Xu X, Ruiz S, Zhang W, Wagner U, Kim A, Ren B, Li Y, Goebl A, Kim J, Soligalla RD, Dubova I, Thompson J, Yates J 3rd, Esteban CR, Sancho-Martinez I, Izpisua Belmonte JC.

Nature. 2012 Nov 22;491(7425):603-7. doi: 10.1038/nature11557.

9.

I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway.

Ohta E, Nihira T, Uchino A, Imaizumi Y, Okada Y, Akamatsu W, Takahashi K, Hayakawa H, Nagai M, Ohyama M, Ryo M, Ogino M, Murayama S, Takashima A, Nishiyama K, Mizuno Y, Mochizuki H, Obata F, Okano H.

Hum Mol Genet. 2015 Sep 1;24(17):4879-900. doi: 10.1093/hmg/ddv212.

PMID:
26056228
10.

Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, Elder GA, Rice ME, Yue Z.

J Neurosci. 2010 Feb 3;30(5):1788-97. doi: 10.1523/JNEUROSCI.5604-09.2010.

11.

Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.

Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG.

Int J Biol Sci. 2011;7(6):753-61.

12.

(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Chen CY, Weng YH, Chien KY, Lin KJ, Yeh TH, Cheng YP, Lu CS, Wang HL.

Cell Death Differ. 2012 Oct;19(10):1623-33. doi: 10.1038/cdd.2012.42.

13.

Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.

Vitte J, Traver S, Maués De Paula A, Lesage S, Rovelli G, Corti O, Duyckaerts C, Brice A.

J Neuropathol Exp Neurol. 2010 Sep;69(9):959-72. doi: 10.1097/NEN.0b013e3181efc01c.

PMID:
20720502
14.

A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.

Dusonchet J, Kochubey O, Stafa K, Young SM Jr, Zufferey R, Moore DJ, Schneider BL, Aebischer P.

J Neurosci. 2011 Jan 19;31(3):907-12. doi: 10.1523/JNEUROSCI.5092-10.2011.

15.

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.

Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ.

Neurobiol Dis. 2015 May;77:49-61. doi: 10.1016/j.nbd.2015.02.019.

PMID:
25731749
16.

Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.

Gomez A, Ferrer I.

Acta Neuropathol. 2010 Aug;120(2):155-67. doi: 10.1007/s00401-010-0669-y.

PMID:
20232069
17.

G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy.

Yakhine-Diop SM, Bravo-San Pedro JM, Gómez-Sánchez R, Pizarro-Estrella E, Rodríguez-Arribas M, Climent V, Aiastui A, López de Munain A, Fuentes JM, González-Polo RA.

Toxicology. 2014 Oct 3;324:1-9. doi: 10.1016/j.tox.2014.07.001.

PMID:
25017139
18.

The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.

Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

BMC Med. 2008 Nov 5;6:32. doi: 10.1186/1741-7015-6-32.

19.

Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death.

Angeles DC, Gan BH, Onstead L, Zhao Y, Lim KL, Dachsel J, Melrose H, Farrer M, Wszolek ZK, Dickson DW, Tan EK.

Hum Mutat. 2011 Dec;32(12):1390-7. doi: 10.1002/humu.21582.

PMID:
21850687
20.

LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.

Sanders LH, Laganière J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschon DE, Vangipuram M, Sundararajan R, Urnov FD, Langston JW, Gregory PD, Zhang HS, Greenamyre JT, Isacson O, Schüle B.

Neurobiol Dis. 2014 Feb;62:381-6. doi: 10.1016/j.nbd.2013.10.013.

Items per page

Supplemental Content

Support Center